Cargando…
Bone-Targeted Agents in Breast Cancer: Do We Now Have All the Answers?
The bone-targeted agents (BTAs), bisphosphonates and denosumab, have an established role in the treatment of metastatic breast cancer bone disease and the prevention of cancer-treatment-induced bone loss. Evidence in support of their ability to improve survival in early breast cancer now indicates t...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751527/ https://www.ncbi.nlm.nih.gov/pubmed/31555046 http://dx.doi.org/10.1177/1178223419843501 |